Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person19
Evercore Inc.
Company
Everpure, Inc.
Company
EverCommerce Inc.
Company
Evergy, Inc.
Company
EVERTEC, Inc.
Company
EverQuote, Inc.
Company
Everforth Inc
Company
electroCore, Inc.
Company
EVgo Inc.
Company
COMSCORE, INC.
Company
Core & Main, Inc.
Company
Evolus, Inc.
Company
Encore Medical, Inc.
Company
Atkore Inc.
Company
Eve Holding, Inc.
Company
EXICURE, INC.
Company
ESG Inc.
Company
Evommune, Inc.
Company
Eva Live Inc
Company
Primary record7
Rapport Therapeutics, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants On October 28, 2026, Rapport Therapeutics, Inc. (the “Company”) entered into an underwriting
Evercore Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition On October 28, 2026, Evercore Inc. issued a press release announcing financial results for its third quarter ended September 30, 2026. A copy of the press release i
Evercore Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2026, the Board of Directors of Evercore Inc. (t
TRex Bio, Inc. filed SCHEDULE 13D
, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this statement, and any amendment or amendments thereto, a copy of which has been filed as Exhibit 99.1 to this Sched
RECURSION PHARMACEUTICALS, INC. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On October 15, 2026, Recursion Pharmaceuticals, Inc. (the Company or Recursion ) entered into an underwriting agreement (the Underwriting Agreement ) with Leerink Pa
Iridium Communications Inc. filed 8-K
Item 8.01. Other Events. On August 26, 2026, Iridium Communications Inc., a Delaware corporation (the Company or Iridium ), filed its definitive proxy statement on Schedule 14A (as such may be supplemented from time to t
Lyntris Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On August 18, 2026, Lyntris Inc. (the Company ) priced the initial public offering (the IPO ) of its common stock, par value $0.001 per share (the Common Stock ), at